CTLA4 and breast carcinoma: Triple therapy, involving radiotherapy alongside anti-CTLA-4 and anti-PD-L1 antibodies, has exhibited notable effectiveness in breast cancer treatment, in which radiotherapy enhances the impact of immune checkpoint inhibitors.